FORMS RELATING TO LISTING

Form F

The Growth Enterprise Market (GEM)

Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: Lee's Pharmaceutical Holdings Limited

Stock code (ordinary shares): 8221

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 2 April 2008.

A. General

Place of incorporation : Cayman Islands

Date of initial listing on GEM : 15 July 2002

Name of Sponsor(s) : Not applicable

Names of directors:

(please distinguish the status of the directors - Executive, Non-Executive or Independent

Non-Executive) : **Executive directors:**

Ms. Lee Siu Fong

Ms. Leelalertsuphakun Wanee

Dr. Li Xiaoyi

Non-Executive director:

Mr. Mauro Bove

Independent Non-Executive directors:

Dr. Chan Yau Ching, Bob Mr. Lam Yat Cheong Dr. Tsim Wah Keung, Karl Name(s) of substantial shareholder(s) (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company :

	Number of Shares held	Percentage of holding
Ms. Lee Siu Fong	130,625,000	31.50%
Ms. Leelalertsuphakun Wanee	130,855,625	31.56%
Huby Technology Limited (note1)	120,290,625	29.01%
Defiante Farmaceutica Lda	123,850,000	29.87%
Dr. Li Xiaoyi	51,080,000	12.32%
Lue Shuk Ping, Vicky (note 2)	51,080,000	12.32%

Notes:

- 1. Huby Technology Limited is legally and beneficially owned as to 50% by Ms. Lee Siu Fong and as to 50% by Ms. Leelalertsuphakun Wanee.
- 2. Lue Shuk Ping, Vicky is the spouse of Dr. Li Xiaoyi.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange

within the same group as the Company : Not applicable

Financial year end date : 31 December

Registered address : PO Box 309 GT, Ugland House, South Church Street,

George Town, Grand Cayman, Cayman Islands

Head office and principal Unit 110-111, Bio-Informatics Centre, No. 2 Science Park

place of business : West Avenue, Hong Kong Science Park, Shatin,

New Territories, Hong Kong

Web-site address (if applicable) : www.leespharm.com

Share registrar : Computershare Hong Kong Investor Services Limited

Auditors : HLM & Co.

B. Business activities

The Group is an integrated research-driven and market-oriented biopharmaceutical group engaged in the development, manufacturing and sales of quality biopharmaceutical products that focus on combating cardiovascular diseases and viral sexually transmitted diseases.

C. Ordinary shares

Number of ordinary

shares in issue : 414,625,000 shares

Par value of ordinary shares in issue: HK\$0.05

Board lot size (in number of shares) : 5,000 shares

Name of other stock exchange(s) on which

ordinary shares are also listed : Not applicable

D. Warrants

Stock code : Not applicable

Board lot size : Not applicable

Expiry date : Not applicable

Exercise price : Not applicable

Conversion ratio : Not applicable

(Not applicable if the warrant is denominated in dollar value of

conversion right)

No. of warrants

outstanding : Not applicable

No. of shares falling to be issued upon the

exercise of outstanding warrants : Not applicable

E. Other securities

Share option scheme:

1,600,000 share options under the pre-IPO share option scheme of the Company adopted on 26 June 2002 had been granted to the Company's director and full-time employees. These share options were granted at a subscription price of HK\$0.280 per share.

16,634,000 share options under the share option scheme of the Company adopted on 26 June 2002 had been granted to the Company's director, full-time employees and consultant. These share options were granted at a subscription price of HK\$0.405, HK\$0.218, HK\$0.159, HK\$0.175 or HK\$0.492 per share.

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to

the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:
By order of the board of directors
Lee Siu Fong